Comment on: Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study: reply.

Mettler, Camille; Terrier, Benjamin; Chouchana, Laurent

Mettler, Camille; Terrier, Benjamin; Chouchana, Laurent.

Mettler C; Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
Terrier B; Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
Chouchana L; Université Paris Descartes, Paris, France.

Rheumatology (Oxford) ; 61(4): e103-e104, 2022 04 11.

Article in English | MEDLINE | ID: covidwho-1556892

Subject(s)

COVID-19; Giant Cell Arteritis; Polymyalgia Rheumatica; COVID-19/prevention & control; COVID-19 Vaccines/adverse effects; Humans; Pharmacovigilance; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Polymyalgia Rheumatica / Giant Cell Arteritis / COVID-19 Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Rheumatology (Oxford) Journal subject: Rheumatology Year: 2022 Document Type: Article Affiliation country: Rheumatology

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google